It was about six months ago when Erin Terjesen opened up her medicine cabinet and realized, to her horror, that she was out of the medication she relied on to keep her headaches from turning into full-blown migraines.
A few minutes later, she stumbled into her pharmacy to search for the medication — Excedrin Migraine — but learned there was none in stock.
Her pharmacist told her that the manufacturer, Novartis, had announced a massive recall of its Excedrin, No-Doz, Bufferin and Gas-X products on Jan. 8.
Six months later, store shelves are still Excedrin-free. Novartis attributed the recall to problems at its Nebraska plant that could have led to contamination by other medications produced there.
In a statement, Novartis said it was “working very hard to return products to store shelves.” The company plans to restart production on a “line-by-line, product-by-product basis” to assure quality, and hopes to start restocking some products in the second half of the year.
There is no word yet on which of the recalled products will be manufactured first.